Business
Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL’s International Liver Congress™ 2022
SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing
About this update from Assembly Biosciences, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., June 22, 2022 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative, investigational therapeutics targeting hepatitis B virus (HBV) and other viral diseases, today announced data from the company’s investigational core inhibitor programs ABI-H3733 (3733), ABI-4334 (4334) and vebicorvir (VBR), featured in six poster presentations at the International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver (EASL) taking place virtually and in London on June 22-26, 2022. “We are excited to present these new data that demonstrate the progress and promising profiles of our next-generation, significantly more potent core inhibitor candidates 3733 and 4334, and that further characterize the profile of VBR,” said John McHutchison, AO, MD, chief executive officer and president of Assembly Bio. “Our enthusiasm for the new tablet formulation of 3733, which is being evaluated in our recently-initiated Phase 1b study, is supported by data presented today demonstrating improved PK parameters preclinically, with plasma levels comparable to the liquid formulation. Additionally, preclinical data presented for 4334, with its best-in-class potential, demonstrates the candidate's potent activity against both cccDNA formation and pre-genomic RNA (pgRNA) encapsidation, supporting our plans to initiate a Phase 1a trial later this year. Finally, the variety of data presented on VBR, currently being evaluated in triple combination studies, continues to build upon this compound’s antiviral potency and clinical profile.” Next-Generation HBV Core Inhibitor Candidates 3733 and 4334 The poster entitled “Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities,” presents pharmacokinetic data on the new tablet (T2) formulation for 3733. In preclinical studies, the T2 formulation at 100 mg dose (predicted human equivalent dose 300mg) showed equivalent plasma serum concentration to the liquid formulation. In HBV patients, the 300 mg dose formulated as the new T2 tablet is projected to achieve exposure that is approximately 150- and 29-fold higher than the protein adjusted EC50 for inhibition of HBV DNA replication and cccDNA forma...